Abstract
In Japan, pancreatic cancer represents the fourth leading cause of death due to cancer. Recently, diagnostic methods and treatment technology for pancreatic cancer has been progressed; however, the mortality rate has not declined. At the time of the initial diagnosis, there are few patients who are resectable absence of the invasion of major vessels or the presence of distant metastasis. The three-year overall survival rate of the patients who were resectable is reported to be only 20%.
Highlights
Introduction and ObjectivesIn Japan, pancreatic cancer represents the fourth leading cause of death due to cancer [1]
We retrospectively investigated 15 patients with locally advanced stage III pancreatic cancer who underwent radiotherapy with or without concurrent chemotherapy at our institution between July 2006 and April 2014
Et al conducted a randomized controlled trial to evaluate the use of chemoradiotherapy for locally advanced pancreatic cancer with Fluorouracil and Cisplatin and chemotherapy alone with Gemcitabine; the authors reported that the survival time of the chemotherapy alone group was significantly better than chemoradiotherapy group in 2008 [12]
Summary
Introduction and ObjectivesIn Japan, pancreatic cancer represents the fourth leading cause of death due to cancer [1]. Diagnostic methods and treatment technology for pancreatic cancer has been progressed; the mortality rate has not declined. The three-year overall survival rate of the patients who were resectable is reported to be only 20% [2]. On the other hand, according to a report from approximately 10-years-ago, the median survival time of the patients who were unresectable was approximately between 6 and 13 months [3-8]. Regardless of the enforcement of surgery, the prognosis of pancreatic cancer is extremely poor compared to other cancers. For patients with unresectable pancreatic cancer, the benefit of the addition of chemotherapy to radiotherapy has proven [8,9]; the effect of the addition of radiotherapy to chemotherapy is unclear [10]. Due to the poor prognosis and insufficient cases of pancreatic cancer, high-quality evidences concerning the treatment strategy are scarce. The purpose of this study is to retrospectively evaluate the efficacy and toxicity of radiotherapy for locally advanced stage III pancreatic cancer in our institution
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
